OrthoPediatrics (KIDS)
(Delayed Data from NSDQ)
$27.19 USD
-0.09 (-0.33%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $27.21 +0.02 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
KIDS 27.19 -0.09(-0.33%)
Will KIDS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KIDS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KIDS
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO
STIM Stock Likely to Gain From Updated TMS Coverage
KIDS: What are Zacks experts saying now?
Zacks Private Portfolio Services
TNDM Stock Likely to Gain From Innovation Amid Competition
EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock
BiomX Stock Gains From Favorable Study Data Presentation on BX004
Other News for KIDS
OrthoPediatrics Corp (KIDS) Shares Down 3.69% on Sep 23
Needham medtech & diagnostics analyst holds analyst/industry conference call
Needham medtech & diagnostics analyst holds analyst/industry conference call
Buy Rating Reaffirmed for OrthoPediatrics on Robust Growth Strategy and Strong Financials
OrthoPediatrics price target raised by $4 at Truist, here's why